Stock ALMDP MEDESIS PHARMA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Medesis Pharma S.A.

Equities

ALMDP

FR0010844464

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 16:35:24 30/04/2024 BST 		5-day change 1st Jan Change
1.24 EUR -6.77% Intraday chart for Medesis Pharma S.A. -15.07% +42.86%
2023 Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 MEDESIS : Invest Securities confirms its recommendation CF

Business Summary

Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment.

The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).

Number of employees: 10

Sales per Business

EUR in Million2019Weight2020Weight Delta
Biopharmaceutical
100.0 %
0 100.0 % 0 100.0 % -9.35%

Sales per region

EUR in Million2019Weight2020Weight Delta
France
100.0 %
0 100.0 % 0 100.0 % -9.35%

Managers

Managers TitleAgeSince
Jean-Claude Maurel CEO
 Chief Executive Officer - 02/04/03
Solene Guilliot CTO
 Chief Tech/Sci/R&D Officer - 31/12/20
Mario Alcaraz SEC
 Corporate Secretary - -

Members of the board

Members of the board TitleAgeSince
Bernard Connes-Lafforet BRD
 Director/Board Member - 11/06/19
Robert Alonso BRD
 Director/Board Member - 26/10/22
Walt Linscott BRD
 Director/Board Member 63 26/10/22
Olivier Connes CHM
 Chairman - 25/09/18
Jean-Marie Cazaledes BRD
 Director/Board Member - 29/06/15
Cédric Navas BRD
 Director/Board Member - 25/09/18
Emmanuel Hebert BRD
 Director/Board Member - 11/06/19
Jean-Philippe Causse BRD
 Director/Board Member - 14/06/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 4,429,081 3,586,229 ( 80.97 %) 0 80.97 %

Shareholders

NameEquities%Valuation
Friedland Gestion SAS
0.1355 %
6,000 0.1355 % 9 882 €

Company contact information

Medesis Pharma SA

L'Orée des Mas avenue du Golf

34670, Baillargues

+33 4 67 03 03 96

http://www.medesispharma.com
address Medesis Pharma S.A.(ALMDP)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEDESIS PHARMA S.A. Stock Medesis Pharma S.A.
+42.86% 5.87M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.53% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.40% 96.09B
ARGENX SE Stock argenx SE
+2.13% 22.28B
BIONTECH SE Stock BioNTech SE
-16.69% 21.4B
GENMAB A/S Stock Genmab A/S
-8.79% 18.14B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.17% 16.09B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.27% 13.83B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.43% 11.97B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALMDP Stock
  4. Company Medesis Pharma S.A.